Skip to main content
SpringerLink
Log in

The use of Recombinant Human Thyrotropin (rhTSH) in the Management of Differentiated Thyroid Cancer

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Robbins J. Pharmacology of bovine and human thyrotropin: an historical perspective. Thyroid 1999;9:451-453.

    Google Scholar 

  2. Wondisford FE, Radovick S, Moates JM, Usala SJ, Weintraub BD. Isolation and characterization of the human thyrotropin betasubunit gene. Differences in gene structure and promoter function from murine species. J Biol Chem 1988;263:12538-12542.

    Google Scholar 

  3. Thotakura NR, Desai RK, Bates LG, Cole ES, Pratt BM, Weintraub BD. Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology 1991;128:341-348.

    Google Scholar 

  4. Szkudlinski MW, Thotakura NR, Bucci I, Joshi LR, Tsai A, East-Palmer J, et al. Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology 1993;133:1490-1503.

    Google Scholar 

  5. Gyves PW, Gesundheit N, Thotakura NR, Stannard BS, DeCherney GS, Weintraub BD. Changes in the sialylation and sulfation of secreted thyrotropin in congenital hypothyroidism. Proc Natl Acad Sci U S A 1990;87:3792-3796.

    Google Scholar 

  6. Miura Y, Perkel VS, Papenberg KA, Johnson MJ, Magner JA. Concanavalin-A, lentil, and ricin lectin affinity binding characteristics of human thyrotropin: differences in the sialylation of thyrotropin in sera of euthyroid, primary, and central hypothyroid patients. J Clin Endocrinol Metab 1989;69:985-995.

    Google Scholar 

  7. Huber GK, Fong P, Concepcion ES, Davies TF. Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab 1991;72:1328-1331.

    Google Scholar 

  8. Braverman LE, Pratt BM, Ebner S, Longcope C. Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in the rhesus monkey. J Clin Endocrinol Metab 1992;74:1135-1139.

    Google Scholar 

  9. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer—[published erratum appears in Am J Med 1995;98:215]. Am J Med 1994;97:418-428.

    Google Scholar 

  10. Mazzaferri EL, Jhiang SM. Differentiated thyroid cancer long-term impact of initial therapy. Trans Am Clin Climatol Assoc 1994;106:151-168.

    Google Scholar 

  11. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1986;61:978-996.

    Google Scholar 

  12. Schlumberger M, De Vathaire F, Travagli JP, Vassal G, Lemerle J, Parmentier C, et al. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab 1987;65:1088-1094.

    Google Scholar 

  13. Welch Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Svec RL, Adair C, et al. Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clin Endocrinol (Oxf ) 1998;49:619-628.

    Google Scholar 

  14. Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 1998;39:1531-1536.

    Google Scholar 

  15. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-1095.

    Google Scholar 

  16. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997;7:265-271.

    Google Scholar 

  17. Robbins J, Merino MJ, Boice JD, Jr., Ron E, Ain KB, Alexander HR, et al. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 1991;115:133-147.

    Google Scholar 

  18. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9:421-427.

    Google Scholar 

  19. Utiger RD. Follow-up of patients with thyroid carcinoma [editorial]. N Engl J Med 1997;337:928-930.

    Google Scholar 

  20. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma ( phase I/II study). J Clin Endocrinol Metab 1994;78:188-196.

    Google Scholar 

  21. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888-896.

    Google Scholar 

  22. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol and Metab 1999;84:3877-3885.

    Google Scholar 

  23. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994;4:49-54.

    Google Scholar 

  24. Park S, Reynolds J, Brucker-Davis F, Whatley M, McEllin K, Maxted D, et al. Iodine kinetics during131-I scanning in patients with thyroid cancer comparison of studies with recombinant human TSH (rhTSH) vs hypothyroidism. J Nucl Med 1966;37:15P-15P.

    Google Scholar 

  25. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488-1492.

    Google Scholar 

  26. Pacini F, Pinchera A, Giani C, Grasso L, Baschieri L. Serum thyroglobulin concentrations and 131I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). Clin Endocrinol (Oxf ) 1980;13:107-110.

    Google Scholar 

  27. Hufner M, Stumpf HP, Grussendorf M, Hermann HJ, Kimmig B. A comparison of the effectiveness of 131I whole body scans and plasma Tg determinations in the diagnosis of metastatic differentiated carcinoma of the thyroid: a retrospective study. Acta Endocrinol (Copenh) 1983;104:327-332.

    Google Scholar 

  28. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest Xrays. J Nucl Med 1988;29:1790-1794.

    Google Scholar 

  29. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-1127.

    Google Scholar 

  30. Anonymous Thyrogen. In: Package Insert Genzyme Corporation. Cambridge, MA, 1998.

  31. Billewicz WZ, Chapman RS, Crooks J, Day ME, Gossage J, Wayne E, et al. Statistical methods applied to the diagnosis of hypothyroidism. Q J Med 1969;38:255-266.

    Google Scholar 

  32. Ringel MD, Ladenson PW. Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. J Clin Endocrinol Metab 1996;81:1724-1725.

    Google Scholar 

  33. Rudavsky AZ, Freeman LM. Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone. J Clin Endocrinol Metab 1997;82:11-14.

    Google Scholar 

  34. Rotman-Pikielny P, Reynolds JC, Barker WC, Yen PM, Skarulis MC, Sarlis NJ. Recombinant human thyrotropin (rhTSH) for the diagnosis and treatment of a highly functional metastatic struma ovarii. J Clin Endocrinol Metab 1999;85:237-244.

    Google Scholar 

  35. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-941.

    Google Scholar 

  36. Maxon HR, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer—a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992;33:1132-1136.

    Google Scholar 

  37. Benua R, Cicale N, Sonenberg M, Rawson R. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol 1962;87:171-182.

    Google Scholar 

  38. Koong SS, Reynolds JC, Movius EG, Keenan AM, Ain KB, Lakshmanan MC, et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999;84:912-916.

    Google Scholar 

  39. Gershengorn MC, Izumi M, Robbins J. Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma. J Clin Endocrinol Metab 1976;42:105-111.

    Google Scholar 

  40. Hershman JM. Recombinant human thyrotropin [editorial]. Thyroid 1999;9:419-420.

    Google Scholar 

  41. Szkudlinski MW, Teh NG, Grossmann M, Tropea JE, Weintraub BD. Engineering human glycoprotein hormone superactive analogues. Nat Biotechnol 1996;14:1257-1263.

    Google Scholar 

  42. Grossmann M, Leitolf H, Weintraub BD, Szkudlinski MW. A rational design strategy for protein hormone superagonists. Nat Biotechnol 1998;16:871-875.

    Google Scholar 

  43. Ringel MD, Ladenson PW, Levine MA. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab 1998;83:4435-4442.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Intramural Research, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD

    Monica C. Skarulis

Authors
  1. Monica C. Skarulis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skarulis, M.C. The use of Recombinant Human Thyrotropin (rhTSH) in the Management of Differentiated Thyroid Cancer. Rev Endocr Metab Disord 1, 147–154 (2000). https://doi.org/10.1023/A:1010018829345

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010018829345

Search

Navigation